Picture of Corvus Pharmaceuticals logo

CRVS — Corvus Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Corvus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

* Corvus Pharmaceuticals Inc  CRVS.OQ  reported a quarterly
adjusted loss of 12 cents​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -17 cents.  The mean expectation of
four analysts for the quarter was for a loss of 13 cents per
share. Wall Street expected results to range from -15 cents
to -12 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Corvus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 12 cents​.
    * The company reported a quarterly loss of $5.7 million.
    * Corvus Pharmaceuticals Inc shares had risen by 7.9% this
quarter and gained 9.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 26.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is $7.50 
This summary was machine generated from LSEG data May 6 at 09:24
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.13          -0.12          Beat
 Dec. 31 2023      -0.12          -0.14          Missed
 Sep. 30 2023      -0.12          -0.12          Met
 Jun. 30 2023      -0.14          -0.14          Met

Recent news on Corvus Pharmaceuticals

See all news